Downloads
Abstract
Background: The androgen receptor has recently emerged as a useful marker for the further refinement of breast cancer subtype classification. Moreover, AR is widely expressed in breast cancers and has been proposed as a therapeutic target in estrogen receptor alpha negative breast cancers that retain AR. This study aims todetermine AR expression and commenting on some relationships between AR expression and some pathological characteristics and survival of patients with ER - negative invasive breast carcinoma.
Methods: 232 ER - ve breast cancer patients were stained by AR marker to classify the BC immunophenotype and evaluating relations to pathological characteristics and survival of BC patients.
Results: Compared with AR-ER-, the AR+ER- immunophenotype was accounted for a high proportion in grade I and II (9.0 and 32.4%), the negative lymph node BCs (74.8%), good and moderate NPI (23.4 and 57.7%), the non - vascular invasion breast cancers (63.1%), as well (p < 0.05 or 0.001). The 5-year OS and DFS rates of this phenotype were 83,593 ± 2,359 and 82,909 ± 2,422 months, respectively which were longer than AR-ER- BCs (p < 0.001).
Conclusions: AR expression of ER - ve breast cancer is often associated with better pathological characteristics and longer survival compared with the negative AR breast cancers.
References
Gucalp A, Tolaney S, Isakoff S, Ingle J, Liu M, Carey L, et al. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. Clin Cancer Res. 2013;19:5505-5512.
Peters AA, Buchanan G, Ricciardelli C, Bianco-Miotto T, Centenera MM, Harris JM, et al. Androgen Receptor Inhibits Estrogen Receptor-α Activity and Is Prognostic in Breast Cancer. Cancer Res. 2009;69:6131-6140.
Vasiliou SK, Diamandis EP. Androgen receptor: a promising therapeutic target in breast cancer. Crit Rev Clin Lab Sci. 2019;56:200-223.
Need EF, Selth LA, Harris TJ, Birrell SN, Tilley WD, Buchanan G. Research resource: interplay between the genomic and transcriptional networks of androgen receptor and estrogen receptor alpha in luminal breast cancer cells. Mol Endocrinol. 2012;26:1941-1952.
Rahim B, O’Regan R. AR signaling in breast cancer. Cancers. 2017;9:21.
McNamara KM, Moore NL, Hickey TE, Sasano H, Tilley WD. Complexities of androgen receptor signalling in breast cancer. Endocrine-Related Cancer. 2014;21:T161-T181.
Giovannelli P, Donato MD, Galasso G, Zazzo ED, Bilancio A, Migliaccio A. The Androgen Receptor in Breast Cancer. Front Endocrinol. 2018;9:492.
Vera - Badillo FE, Templeton AJ, Gouveia Pd, Diaz- Padilla I, Bedard PL, Al-Mubarak M, et al. Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst. 2014 Jan;106:djt319.
Agoff SN, Swanson PE, Linden H, Hawes SE, Lawton TJ. Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. Am. J. Clin. Pathol. 2003;120:725-731.
Niemeier LA, Dabbs DJ, Beriwal S, Striebel JM, Bhargava R. Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor- negative tumors with apocrine differentiation. Modern Pathology. 2010;23:205-212.
Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750-67.
Lehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, Shyr Y, et al. Refinement of Triple - Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PLoS One. 2016;11:e0157368.
Hu R, Dawood S, Holmes MD, Collins LC, Schnitt SJ, Cole K, et al. Androgen receptor expression and breast cancer survival in postmenopausal women. Clin Cancer Res. 2011;17:1867-1874.
Ogawa Y, Hai E, Kanako Matsumoto, Ikeda K, Tokunaga S, Nagahara H, et al. Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers. Int J Clin Oncol. 2008 Oct;13:431-435.
Luo X, Shi Y-X, Li Z-M, Jiang W-Q. Expression and clinical significance of androgen receptor in triple negative breast cancer. Chin J Cancer. 2010;29:585-590.
Park S, Koo J, Park HS, Kim J-H, Choi S-Y, Lee JH, et al. Expression of androgen receptors in primary breastcancer. Ann Oncol. 2010;21:488-492.
Mrklić I, Pogorelić Z, Capkun V, Tomić S. Expression of androgen receptors in triple negative breast carcinomas. Acta Histochem. 2013;15:344-348.
Loibl S, Müller BM, Minckwitz Gv, Schwabe M, Roller M, Darb-Esfahani S, et al. Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat. 2011;130:477-487.
Bhattarai S, Klimov S, Mittal K, Krishnamurti U, Li XB, Oprea - Ilies G, et al. Prognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study. Cancers. 2019;11: 995.
Sutton LM, Cao D, Sarode V, Molberg KH, Torgbe K, Haley B, et al. Decreased androgen receptor expression is associated with distant metastases in patients with androgen receptor - expressing triple - negative breast carcinoma. Am J Clin Pathol. 2012;138:511-516.
Chủ NV. Sự bộc lộ thụ thể androgen và estrogen trong ung thư biểu mô tuyến vú xâm nhập. Y học Việt Nam. 4- 2021;501:58-62.
Abdelaal SE, Gabal SM, Din AAGe, Hosni HN, Sharaf HA. Immunohistochemical Study of Androgen Receptor Expression in Estrogen Receptor - Negative Invasive Breast Carcinoma and its Relation with Clinicopathologic Factors. Access Maced J Med Sci. 2020 Sep 10;8:615-622.
Niemeier LA, Dabbs DJ, Beriwal S, Striebel JM, Bhargava R. Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor - negative tumors with apocrine differentiation. Modern Pathology. 2010;23:205-212.
Cochrane DR, Bernales S, Jacobsen BM, Cittelly DM, Howe EN, D’Amato NC, et al. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Research. 2014;166:R7.
Gerratanaa L, Basilea D, Buonob G, Placidob SD, Giulianob M, Minichilloc S, et al. Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype. Cancer Treatment Reviews. 2018;68:102-110.
Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez - Angulo AM, Meric - Bernstam F, et al. Differential response to neoadjuvant chemotherapy among 7 triple - negative breast cancer molecular subtypes. Clin Cancer Res. 2013 Oct 1;19:5533-5540.
Santonja A, Sánchez - Muñoz A, Lluch A, Chica-Parrado MR, Albanell J, Chacón JI, et al. Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy. Oncotarget. 2018 May 29;9:26406-26416.
He J, Peng R, Yuan Z, Wang S, Peng J, Lin G, et al. Prognostic value of androgen receptor expression in operable triple- negative breast cancer: a retrospective analysis based on a tissue microarray. Med Oncol. 2012 Jun;29:406-410.
Wang X, Bi X, Huang Z, Huang J, Xia W, Shi W, et al. The prognostic value of AR in HER2 - enriched metastatic breast cancer. Endocr Relat Cancer. 2020;27:199-208.
| Published | 04-08-2022 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | No. 82 (2022) | |
| Section | Original article | |
| DOI | 10.38103/jcmhch.82.11 | |
| Keywords | Thụ thể androgen, Giải phẫu bệnh, Sống thêm, Ung thư vú Androgen receptor, Pathology, Survival, Breast cancer |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2025 Journal of Clinical Medicine Hue Central Hospital